CNS International Prognostic Index in Diffuse Large B-Cell Lymphoma (CNS-IPI)
Estimate risk of CNS relapse/progression in diffuse large B-cell lymphoma
CNS recurrence/progression in patients with DLBCL can be devastating. Although some studies suggest a decline in the occurrence of CNS relapse in the rituximab era, certain high risk groups can still be identified and should be considered for CNS-directed trials or prophylactic therapies.
The CNS-IPI was derived from a population of patients (n=2164) enrolled in the German clinical trials and subsequently validated in a population of 1597 patients treated in British Columbia, Canada. The score is based on the original IPI factors with the addition of kidney and/or adrenal involvement. The final score is able to differentiate patients into 3 distinct prognostic groups for CNS recurrence/progression.
Schmitz, et al.
Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2016 September 10, 34 (26): 3150-6
The CNS International Prognostic Index in Diffuse Large B-Cell Lymphoma (CNS-IPI) calculator is created by QxMD.